NCT05439876

Brief Summary

The purpose of this study is to evaluate the effect of melatonin for improving sleep in pediatric epilepsy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
147

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 30, 2022

Completed
18 days until next milestone

Study Start

First participant enrolled

July 18, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 3, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 3, 2025

Completed
8 months until next milestone

Results Posted

Study results publicly available

August 29, 2025

Completed
Last Updated

August 29, 2025

Status Verified

August 1, 2025

Enrollment Period

2.5 years

First QC Date

June 20, 2022

Results QC Date

June 2, 2025

Last Update Submit

August 28, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sleep Onset Latency

    Sleep onset latency was assessed by actigraphy.

    4 weeks

Secondary Outcomes (1)

  • Children's Sleep Disturbance

    4 weeks

Study Arms (2)

Melatonin

EXPERIMENTAL

Melatonin

Drug: Melatonin

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

Melatonin 2 mg daily for 4 weeks

Also known as: Melatonin supplement
Melatonin

Placebo daily for 4 weeks

Also known as: Starch pill
Placebo

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • \- Children aged between 1 and 18 years with a confirmed diagnosis of epilepsy and with sleep problems

You may not qualify if:

  • Children who are bedridden with limited mobility
  • Children with liver or kidney dysfunction
  • Children on hypnotics, antidepressants, or anxiolytics within 4 weeks before the baseline clinic visit
  • Adolescent girls who are pregnant or breastfeeding
  • Adolescent girls who have sexual activities but cannot take effective contraceptive measures during the trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, 10051, Taiwan

Location

MeSH Terms

Interventions

MelatoninStarch

Intervention Hierarchy (Ancestors)

TryptaminesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsHormonesHormones, Hormone Substitutes, and Hormone AntagonistsGlucansBiopolymersPolymersMacromolecular SubstancesDietary CarbohydratesCarbohydratesPolysaccharides

Results Point of Contact

Title
Shao-Yu Tsai
Organization
School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan

Study Officials

  • Wang-Tso Lee

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 20, 2022

First Posted

June 30, 2022

Study Start

July 18, 2022

Primary Completion

January 3, 2025

Study Completion

January 3, 2025

Last Updated

August 29, 2025

Results First Posted

August 29, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations